UltraSight Raises $24 Million to Bring AI-Guided Heart Scans to More U.S. Hospitals

More U.S. hospitals could soon have a way for trained clinicians who are not ultrasound specialists to capture heart scans. UltraSight has raised $24 million in Series B2 financing to widen use of its AI-guided platform and develop tools for intensive care and circulatory support. The expansion will test whether a guided scan can fit into more time-sensitive clinical work without removing physician oversight.

UltraSight’s Echosystem combines structured training, real-time AI guidance and analytics for focused heart ultrasound exams. Its intended users are trained clinical providers, with qualified physicians overseeing the work and retaining responsibility for interpretation and reporting. The software has FDA clearance to assist medical professionals in performing cardiac ultrasound scans; that clearance should not be confused with a claim that the AI can independently deliver a diagnosis.

UltraSight says Echosystem is already deployed at more than 10 commercial sites, including intensive care settings. That is a foothold, not the wider U.S. adoption the financing is meant to support. The company plans to spend the new capital on commercial expansion, strategic collaborations and workflows for intensive care units and circulatory support settings, where its announcement says imaging decisions can shape patient management.

Alive HealthTech Growth Fund led the round. Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures participated, along with existing investors Mayo Clinic Ventures, NYU and Iron Nation. UltraSight did not describe the financing as a new clinical product release: the stated use of the money is to take its existing product line further into U.S. health systems and build additional workflows around it.

To make the case for broader access, UltraSight points to a study published in JAMA Cardiology in August. Novice operators used AI guidance to acquire cardiac ultrasound images, which were then used for automated detection of moderate or worse aortic stenosis, a narrowing of a heart valve. The reported sensitivity was 93% and specificity was 96%. Those figures concern detection from the acquired images, not an AI system making every clinical decision in the examination.

93%Sensitivity

The cited study reported 93% sensitivity for automated detection of moderate or worse aortic stenosis using images acquired by novice operators with AI guidance.

96%Specificity

The same study reported 96% specificity for that detection task.

The distinction matters for the expansion UltraSight is funding. Acquiring an image, detecting signs of one valve condition and managing a patient in intensive care are different tasks. The study result supports a particular screening workflow; it does not establish how the proposed intensive care or circulatory support tools will perform. UltraSight says the findings point to a way to identify patients who may need further evaluation, not to replace that evaluation.

The financing also comes with changes to UltraSight’s board. Rick Geoffrion was recently appointed chairman; the company says he has more than 30 years of experience in cardiovascular devices and commercialization. It also named incoming directors from three investors in the round: Alive’s Dudi Klein, Star51 Capital’s Tal Wenderow and Deep Insight’s Barak Ben-Eliezer.

Geoffrion describes access to reliable ultrasound imaging as dependent on a scarce group of experts. That explains the company’s emphasis on helping other trained clinicians capture scans, while keeping interpretation with physicians. The question for U.S. expansion is how widely that supervised model can be adopted beyond the commercial sites UltraSight already counts.

One financial tie is worth keeping visible as UltraSight presents its clinical case: Mayo Clinic Ventures participated as an existing investor, and the announcement discloses that Mayo Clinic has a financial interest in the technology it discusses. The round gives UltraSight money to pursue wider use. Its next measure of progress will be adoption of the guided workflow and evidence for the additional clinical settings it wants to serve.